Zoetis Inc.

ZTS Healthcare Drug Manufacturers Specialty & Generic

Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.

79.20 0.78 +0.99%
Market cap
$32.4B
P/E
13.0×
Fwd P/E
12.3×
Dividend yield
2.64%
F-score
7/9
Altman Z
5.73
Beneish M
−2.45
Dividend safety
88/100

Zoetis Inc. 10-K filed Feb 12, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:49 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business, against the 10-K filed Feb 13, 2025: 8 added · 2 removed · 51 modified; 18 with only figures updated

  1. Modified · Overview

    Zoetis Inc. is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. We have a diversified business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within seven major product categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical and animal health diagnostics. For over 70 With a legacy of nearly 75 years, we have been innovatingcontinue to pioneer ways to predict, prevent, detect, and treat animal illness, and continue to stand bysupporting those raising and caring for animals worldwide - from veterinarians and pet owners to livestock producers.

60 more changes in this Item, word by word, in Powerpack.

Powerpack